Skip to main content
Retour
SANA logo

Sana Biotechnology, Inc.

Qualité des données : 100%
SANA
NASDAQ Healthcare Biotechnology
3,12 €
▲ 0,01 € (0,32%)
Cap. Boursière : 832,62M
Fourchette du Jour
3,10 € 3,25 €
Fourchette 52 Semaines
1,26 € 6,55 €
Volume
1 343 781
Moyenne 50J / 200J
4,05 € / 3,93 €
Clôture Précédente
3,11 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -3,4 0,4
P/B 5,2 2,9
ROE % -118,7 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,5 0,2

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Mar 9, 2026
Wyrick Susan D.
See Remarks
other 4 387 3,13 € 13 700 €
Mar 9, 2026
Harr Steve
President & CEO
other 24 345 3,13 € 75 815 €
Mar 7, 2026
Wyrick Susan D.
See Remarks
other 6 500
Mar 7, 2026
Harr Steve
President & CEO
other 100 000
Mar 6, 2026
Wyrick Susan D.
See Remarks
other 20 832
Mar 6, 2026
Harr Steve
President & CEO
other 83 332
Mar 5, 2026
Harr Steve
President & CEO
grant 1 100 000
Mar 5, 2026
Wyrick Susan D.
See Remarks
grant 252 083
Mar 3, 2026
Wyrick Susan D.
See Remarks
other 491 3,91 € 1 920 €
Mar 2, 2026
Wyrick Susan D.
See Remarks
other 3 050
Feb 17, 2026
Piper Brian
EVP, Chief Financial Officer
grant 1 100 000
Dec 15, 2025
Wyrick Susan D.
See Remarks
other 873 5,22 € 4 557 €
Dec 13, 2025
Wyrick Susan D.
See Remarks
other 6 800
Dec 4, 2025
Wyrick Susan D.
See Remarks
other 2 565 4,44 € 11 389 €
Dec 3, 2025
Wyrick Susan D.
See Remarks
other 20 000
Jun 5, 2025
Rosiello Robert L.
grant 115 000
Jun 5, 2025
Wilderotter Mary Agnes
grant 80 000
Jun 5, 2025
NELSEN ROBERT
grant 80 000
Jun 5, 2025
Bilenker Joshua H.
grant 80 000
Jun 5, 2025
Yang Patrick Y
grant 80 000

Points Clés

Debt/Equity of 0,49 — conservative balance sheet
Negative free cash flow of -144,77M
PEG of 0,24 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-118,70%
ROIC-59,74%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,49
Current Ratio1,89
Interest Coverage0,00

Valorisation

P/E Ratio
-3,41
P/B Ratio5,18
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -244,17M
ROE -118,70% ROA -58,57%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -144,77M
ROIC -59,74% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,49 Current Ratio 1,89
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -3,41 P/B Ratio 5,18
P/S Ratio N/A PEG Ratio 0,24
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 832,62M Enterprise Value 839,62M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -244,17M -266,76M -283,26M -269,48M -355,93M
EPS (Diluted) -0,96 -1,16 -1,46 -1,43 -2,14
Gross Profit -12,75M 0,0 0,0 0,0 0,0
Operating Income -190,96M -272,72M -293,14M -272,56M -356,91M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 416,89M 501,02M 565,30M 822,72M 1,13B
Total Liabilities 256,01M 250,52M 277,79M 323,41M 400,91M
Shareholders' Equity 160,88M 250,50M 287,51M 499,32M 728,50M
Total Debt 78,86M 94,20M 104,10M 108,25M 110,94M
Cash & Equivalents 71,87M 127,57M 133,52M 176,77M 253,03M
Current Assets 148,68M 160,81M 213,52M 444,44M 558,10M
Current Liabilities 78,73M 45,43M 64,49M 111,50M 99,24M